.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Argus Health
US Department of Justice
Fuji
Mallinckrodt
UBS
Moodys
Cipla
QuintilesIMS
Colorcon

Generated: September 20, 2017

DrugPatentWatch Database Preview

Pegaptanib sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for pegaptanib sodium and what is the scope of pegaptanib sodium freedom to operate?

Pegaptanib sodium
is the generic ingredient in one branded drug marketed by Valeant Pharms Llc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegaptanib sodium has three hundred and sixty-seven patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for Generic Name: pegaptanib sodium

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2,403
Drug Prices:see low prices
DailyMed Link:pegaptanib sodium at DailyMed

Pharmacology for Ingredient: pegaptanib sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pegaptanib sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pegaptanib sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,291,184 Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex► Subscribe
5,503,978 Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase► Subscribe
5,763,173 Nucleic acid ligand inhibitors to DNA polymerases► Subscribe
6,344,318 Methods of producing nucleic acid ligands► Subscribe
5,763,566 Systematic evolution of ligands by exponential enrichment: tissue SELEX► Subscribe
5,622,828 High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA.sub.2)► Subscribe
5,723,592 Parallel selex► Subscribe
6,013,443 Systematic evolution of ligands by exponential enrichment: tissue SELEX► Subscribe
5,861,254 Flow cell SELEX► Subscribe
5,773,598 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pegaptanib sodium

Country Document Number Estimated Expiration
European Patent Office1144669► Subscribe
World Intellectual Property Organization (WIPO)9521853► Subscribe
China1164760► Subscribe
European Patent Office0840742► Subscribe
Spain2321243► Subscribe
Japan2010265300► Subscribe
Australia733674► Subscribe
Spain2110444► Subscribe
Canada2219119► Subscribe
Canada2219807► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PEGAPTANIB SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C024/2006Ireland► SubscribeSPC024/2006:, EXPIRES: 20210130
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
2006 00021Denmark► Subscribe
2006004Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C0021France► SubscribePRODUCT NAME: PEGAPTANIB EN PARTICULIER SOUS FORME DE SON SEL DE SODIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/05/325/001 DU 20060131; REGISTRATION NO/DATE AT EEC: EU/1/05/325/001 DU 20060131
252Luxembourg► Subscribe91252, EXPIRES: 20210131
0957929/01Switzerland► SubscribePRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Army
Deloitte
McKesson
Cipla
Covington
Argus Health
Medtronic
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot